VAXINIA is under clinical development by Imugene and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VAXINIA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VAXINIA overview

VAXINIA (CF33+hNIS) is under development for the treatment of solid tumor, colon cancer, colorectal cancer, triple negative breast cancer, pancreatic cancer, non-small cell lung cancer, urothelial cancer, metastatic melanoma, bladder cancer, head and neck cancer, renal cell cancers and gastrointestinal cancer. It is administered through parenteral, intratumoral and intravenous routes. The drug candidate is a chimeric vaccinia, derived through a recombination of genetic sequences from multi pox virus strains. It comprises of oncolytic virus CF33 with the human sodium iodide symporter (hNIS). 

Imugene overview

Imugene is a clinical-stage biopharmaceutical company that focuses on the development of vaccines in the area of oncology immune. The company develops immunotherapies that activate the immune system of cancer patients to identify and eradicate tumors. The company’s pipeline products include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, IGF-1R, HER-1, and HER-3 for the treatment of various tumors including gastric, breast, lung cancers. Imugene’s lead product candidate, CF33 is a chimeric vaccinia poxvirus for the treatment of mixed advanced solid tumors (MAST) and metastatic triple-negative breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. Imugene is headquartered in Sydney, New South Wales Australia.

For a complete picture of VAXINIA’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.